Epidemiological Studies and Risk Factor Analysis of GERD in Xiamen City
Key facts
- Who runs it
- Zhongshan Hospital (Xiamen), Fudan University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 1,625 people enrolled
- Started
- 1 Aug 2024
- Ended
- 31 Oct 2025
- Type of study
- Observational
- Record updated
- 13 March 2026
Who can take part
- Age
- 16 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (9)Hide the full registry criteria
Who can take part
- All patients had experienced typical reflux symptoms, i.e., mild heartburn and/or regurgitation symptoms, for at least 2 days per week or moderate/severe reflux symptoms for more than 1 day per week during the previous 3 months and had upper endoscopy examinations in the previous month
- Cooperate with the questionnaire survey
- Volunteer and sign the informed consent form
- Permanent residents in Xiamen
Who cannot take part
- Malignant tumor
- Failing to cooperate with the investigation because of the factors such as education level and language intelligence disorder, etc
- Patients with severe heart, lung, kidney, liver, blood, nerve, endocrine and mental system diseases
- Partial or total gastrectomy
- Patients with mental retardation, etc
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Gastroesophageal Reflux Disease (GERD) is a condition characterized by the reflux of gastric and duodenal contents into the esophagus, primarily manifested by symptoms such as acid regurgitation and heartburn. GERD significantly affects patients' daily lives and health-related quality of life. Prolonged gastroesophageal reflux can lead to repeated irritation of the esophageal mucosa by gastric acid and acidic gastric contents, resulting in the replacement of normal squamous epithelium in the lower esophagus with metaplastic columnar epithelium. This pathological change, known as Barrett's Esophagus (BE), is considered a precancerous lesion for esophageal adenocarcinoma.
The group in the trial
- Gastroesophageal Reflux Disease
Gastroesophageal reflux disease (GERD) is a gastrointestinal motility disorder that results from the reflux of stomach contents into the esophagus or oral cavity resulting in symptoms or complications.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Epidemiological Studies and Risk Factor Analysis of Gastroesophageal Reflux Diseases in Xiamen City: a Cross-sectional Study
- Record updated
- 13 March 2026